Related by context. All words. (Click for frequent words.) 71 relapsed MM 70 rFSH 68 chemoradiation therapy 68 pegylated liposomal doxorubicin 68 gemcitabine cisplatin 68 postoperative chemotherapy 67 NMIBC 67 Platinol ® cisplatin 67 STRIDE PD 67 Pemetrexed 67 unresectable tumors 67 lenalidomide Revlimid R 67 PSMA ADC 67 interferon ribavirin 67 biochemical relapse 67 sargramostim 67 YONDELIS 67 NSABP B 66 galiximab 66 RECORD1 66 recurrent glioblastoma multiforme 66 Renal Cell Carcinoma RCC 66 dacarbazine chemotherapy 66 neoadjuvant treatment 66 antiretroviral naïve 66 tipranavir r 66 echocardiographic parameters 66 BCIRG 66 liposomal doxorubicin 66 CIMZIA ™ 66 haematologic 66 autologous SCT 66 melphalan prednisone 66 achieved CCyR 66 pomalidomide 66 nonsmall cell lung cancer 66 colesevelam HCl 66 concurrent chemoradiation 66 clinically localized prostate 66 hepatorenal syndrome 66 metastatic lung cancer 66 metastatic neuroendocrine tumors 65 busulfan 65 Bezielle 65 gp# vaccine 65 teriflunomide 65 HSCT 65 BCG refractory 65 histologically confirmed 65 preoperative chemotherapy 65 mitoxantrone chemotherapy 65 resected pancreatic cancer 65 ZACTIMA 65 MGd 65 AGILECT R 65 HER2 overexpression 65 adriamycin 65 paclitaxel Taxol R 65 radiotherapy RT 65 IFN alfa 65 anthracycline taxane 65 MAGE A3 ASCI 65 mitoxantrone plus 65 Naive Patients 65 thalidomide Thalomid 65 chemoradiotherapy 65 ABVD 65 FOLFOX4 65 Fludarabine 65 CTAP# Capsules 65 metastatic malignant 65 erlotinib Tarceva ® 65 underwent resection 65 gefitinib Iressa 65 Platinol ® 65 HER2 positive metastatic breast 65 Xelox 65 lumbar spine BMD 65 certolizumab 65 samalizumab 65 CYT# potent vascular disrupting 65 ARB telmisartan 65 colorectal liver metastases 65 pT3 65 cisplatin gemcitabine 65 #F FDG PET 65 relapsing multiple sclerosis 65 epirubicin 65 gemcitabine carboplatin 65 Doxil ® 65 chemo radiotherapy 65 underwent surgical resection 65 Folfox 65 mutated KRAS 65 debulking surgery 65 antiangiogenic therapy 65 Degarelix 65 CC genotype 65 salmeterol fluticasone 64 Natalizumab 64 antithymocyte globulin 64 elective PCI 64 CRp 64 epoetin alpha 64 CIMZIA TM certolizumab pegol 64 basal bolus regimen 64 genotypic resistance 64 stage IIIb IV 64 PASI scores 64 refractory CLL 64 ritonavir boosted 64 Alkeran 64 cyclophosphamide doxorubicin vincristine 64 oral antidiabetic medication 64 PSA nadir 64 phase IIb study 64 chemotherapy cisplatin 64 5 Fluorouracil 64 estramustine 64 Follicular Lymphoma 64 Decitabine 64 refractory chronic lymphocytic 64 deep venous thromboses 64 dasatinib Sprycel 64 azilsartan medoxomil 64 Ceplene/IL-2 64 caspofungin 64 dose melphalan 64 recurrent glioblastoma 64 interferon gamma 1b 64 relapsing remitting MS RRMS 64 pancreatic adenocarcinoma 64 FOLFOX6 64 colorectal adenoma 64 ZOLINZA 64 cediranib 64 rindopepimut 64 standard chemotherapy regimen 64 TEMSO 64 capecitabine Xeloda 64 Interferon beta 64 Pertuzumab 64 ALT elevation 64 MVA MUC1 IL2 64 Oncotype 64 oral clodronate 64 mutated K ras 64 peritoneal carcinomatosis 64 randomized multicenter Phase III 64 operable breast cancer 64 KRAS status 64 tumor histology 64 corifollitropin alfa 64 intradermal injections 64 Intravenous immunoglobulin 64 symptomatic VTE 64 Neoadjuvant 64 dose escalation phase 64 allogeneic HSCT 64 Peginterferon 64 CHAMPION PCI 64 TURBT 64 urocortin 2 64 recurrent NSCLC 64 eribulin mesylate 64 β blockers 64 CHOP chemotherapy 64 cilengitide 64 paclitaxel Taxol ® 64 #F FDG 64 androgen suppression 64 non squamous histology 64 comparator arm 64 APTIVUS R 64 BEXXAR Therapeutic Regimen 64 NATRECOR R 64 dacarbazine DTIC 64 miconazole Lauriad ® 64 GW# [003] 64 doxorubicin cyclophosphamide 64 LHRH receptor positive 64 BENICAR HCT 64 elotuzumab 64 relapsed ovarian cancer 64 iniparib BSI 64 Zemplar Capsules 63 recurrent GBM 63 PEGylated interferon 63 PEG IFN 63 biliary tract cancer 63 invasive lobular carcinoma 63 Gastrointestinal Stromal Tumors 63 K ras mutations 63 trabectedin 63 sunitinib malate 63 dosing cohort 63 metaglidasen 63 hA# 63 TMC# r 63 APTIVUS r 63 smoldering myeloma 63 intravesical therapy 63 Tumor Response 63 ATACAND 63 PSADT 63 Inhaled nitric oxide 63 platelet inhibitor 63 Velcade bortezomib 63 Pegylated Interferon 63 Xcellerated T Cells 63 Aptivus ® 63 Arranon 63 adjuvant cisplatin 63 basal cell carcinoma BCC 63 clinically evaluable 63 Epirubicin 63 sorafenib Nexavar ® 63 fluoropyrimidine 63 lumiliximab 63 mycophenolate mofetil MMF 63 adjuvant systemic 63 sorafenib Nexavar 63 trastuzumab Herceptin R 63 Navelbine ® 63 adjuvant radiotherapy 63 medically inoperable 63 tumor xenograft models 63 APTIVUS 63 metastatic renal cell carcinoma 63 stratifying patients 63 refractory AML 63 low dose cytarabine 63 Bayer HealthCare Onyx Pharmaceuticals 63 Thal Dex 63 regorafenib 63 5-FU/LV 63 CINQUIL 63 TEMODAL 63 CR nPR 63 immunomodulatory therapy 63 bendamustine 63 prostate carcinoma 63 tipranavir ritonavir 63 zoledronate 63 reduce serum phosphate 63 elacytarabine 63 Cardiotoxicity 63 somatostatin analog 63 metastatic GIST 63 oxaliplatin Eloxatin 63 daunorubicin 63 epoetin beta 63 abacavir Ziagen 63 sorafenib tablets 63 leukemia AML 63 hormone receptor negative 63 paricalcitol 63 riociguat 63 folinic acid 63 sitaxsentan 63 #mg ATC 63 evaluating tivozanib 63 papillary renal cell carcinoma 63 etanercept Enbrel 63 mycophenolate mofetil 63 Quinamed 63 treatment naive genotype 63 EndoTAGTM 1 63 recombinant erythropoietin 63 Gliadel Wafer 63 hepatocellular carcinomas 63 ancrod 63 intracranial hemorrhage ICH 63 NATRECOR ® 63 sipuleucel T 63 follicular lymphomas 63 haematological cancers 63 Androxal TM 63 epirubicin cyclophosphamide 63 ONTAK 63 metastatic colorectal carcinoma 63 heavily pretreated patients 63 chemotherapeutic regimen 63 GetGoal Phase III 63 CAELYX 63 cytoreduction 63 angiographic outcomes 63 letrozole Femara 63 aromatase inhibitor therapy 63 canakinumab 63 INSPIRE Trial Phase III 63 CALGB 63 Temsirolimus 63 VELCADE melphalan 63 Adjuvant chemotherapy 63 gemtuzumab ozogamicin 63 azacytidine 63 abacavir lamivudine 63 completely resected 63 receptor tyrosine kinase inhibitor 63 CANCIDAS 63 liver resection 63 vincristine doxorubicin 63 REMINYL ® 63 neoadjuvant therapy 63 daily subcutaneous injections 63 dexamethasone Decadron 63 KRAS mutations occur 63 anthracyclines taxanes 63 CRLX# 63 stage IIIB 63 #mg/m# [001] 63 Pharmacokinetic parameters 63 PROCRIT ® 63 Radical prostatectomy 63 recurrent metastatic 62 BEXXAR 62 visilizumab 62 Targretin capsules 62 evaluating REVLIMID 62 liposomal amphotericin B 62 dopamine partial agonist 62 induce remission 62 mg/m2 dose 62 neoadjuvant chemotherapy 62 octreotide LAR 62 Acute Myeloid Leukaemia AML 62 cinacalcet 62 Kahalalide F 62 KRAS wild 62 docetaxel Taxotere ® 62 virological response 62 refractory CTCL 62 gemcitabine Gemzar ® 62 FUSILEV enhances 62 allogeneic transplant 62 corticosteroid dose 62 PORxin TM platforms 62 decitabine 62 squamous histology 62 F FDG PET 62 prospectively stratified 62 metastatic RCC 62 weekly subcutaneous injections 62 intravenous cyclophosphamide 62 oral hypoglycemic agent 62 thrombocytopenic 62 patients receiving myelosuppressive 62 Interferon alfa 62 radiation chemoradiation 62 pegylated interferon alfa 62 forodesine 62 BrachySil TM 62 Tarceva TM 62 FOLFIRI 62 refractory indolent non 62 IMA# 62 non squamous NSCLC 62 EOquin TM 62 mesalamine granules 62 Telintra 62 PEG SN# 62 Anthracycline 62 achieved ACR# 62 rituximab Rituxan 62 pharmacologically active isomer 62 pegylated interferon alpha 2a 62 Bendamustine 62 Myelofibrosis 62 iniparib 62 FASLODEX 62 imatinib therapy 62 complete cytogenetic response 62 bortezomib refractory 62 E1 INT TM 62 T1c 62 divalproex sodium 62 neurologic progression 62 alvespimycin 62 cytokine refractory 62 Cariprazine 62 metastatic bladder 62 methotrexate therapy 62 adjuvant tamoxifen 62 biologic DMARD 62 prospective multicentre 62 superficial bladder cancer 62 paclitaxel carboplatin 62 adenoma recurrence 62 bacillus Calmette Guerin 62 prednisone prednisolone 62 rosuvastatin #mg 62 calcineurin inhibitor 62 Talotrexin 62 insulin detemir 62 demonstrated antitumor activity 62 LHRH agonists 62 clinically meaningful reductions 62 PROSTVAC ® 62 progression TTP 62 histological subtype 62 trastuzumab Herceptin ® 62 thetreatment 62 TO AVOID PREGNANCY WHILE 62 Newly Diagnosed Multiple Myeloma 62 moderate renal impairment 62 cranial radiation 62 liver metastasis 62 hematopoietic cancers 62 FDG PET imaging 62 DEB# 62 custirsen 62 Cyclophosphamide 62 symptomatic paroxysmal AF 62 CYPHER Stent 62 Flu Cy 62 lipid lowering agents 62 LV dysfunction 62 clevidipine 62 ara C 62 recurrent malignant glioma 62 HIV coinfected 62 ACTEMRA TM 62 BR.# 62 TTF Therapy 62 Amrubicin 62 autologous transplants 62 peginterferon alpha 2a 62 VTE prophylaxis 62 Capesaris 62 postoperative mortality 62 infusional 62 prospectively randomized 62 PROSTVAC VF 62 microbiological eradication 62 goserelin 62 docetaxel chemotherapy 62 follicular lymphoma FL 62 Myelodysplastic Syndrome MDS 62 cyclophosphamide methotrexate 62 Venous thromboembolism 62 TIMP 1 62 BladderChek 62 Femara letrozole 62 baseline LDH 62 ribavirin RBV 62 SPRYCEL ® 62 nonmetastatic 62 EOquin TM phase 62 diabetes mellitus DM 62 neoadjuvant 62 methotrexate monotherapy 62 tarenflurbil 62 CLL SLL 62 bovine thrombin 62 nalbuphine ER 62 FOLFIRI alone 62 metastatic carcinoid tumors 62 Dasatinib 62 novel VDA molecule 62 HER2 expression 62 nonsquamous 62 Procoralan 62 intermittent dosing 62 refractory ovarian cancer 62 cardiac perfusion 62 steroid dexamethasone 62 refractory metastatic 62 refractory multiple myeloma 62 Chronic lymphocytic leukemia 62 Mg Usa 62 naïve HCV 62 bronchoalveolar lavage 62 8mg/kg 62 LymphoStat B belimumab 62 oral rivaroxaban 62 protease inhibitor PI 62 adalimumab Humira 62 Relapsing Remitting Multiple Sclerosis 62 MabCampath 62 liposomal formulation 62 aspirin clopidogrel 62 Actimmune ® 62 intra arterial chemotherapy 62 GnRH agonist 62 secondary hyperparathyroidism 62 anagrelide 62 ug dose 62 Juvenile Idiopathic Arthritis 62 Chemoradiation 62 Chronic Renal Failure 62 VFEND 62 unresectable HCC 62 CLARITY study 62 pancreatic insufficiency 62 evaluating mipomersen 62 metastatic CRC 62 lenalidomide dexamethasone 61 cisplatin resistant 61 Papillary 61 rHuEPO 61 budesonide foam 61 locoregional 61 squamous cell lung cancer 61 overt nephropathy 61 null responder 61 CIMZIA TM 61 pain palliation 61 SERCA2a 61 neo adjuvant 61 Hormone Refractory Prostate Cancer 61 sevelamer 61 Squamous 61 double blinded randomized 61 antibiotic regimens 61 TASKi3 61 venlafaxine XR 61 xanthine oxidase inhibitor 61 candidemia 61 glycosylated hemoglobin HbA1c 61 adjuvant radiation 61 HBeAg seroconversion 61 recombinant follicle stimulating 61 phase IIIb 61 DLQI 61 docetaxel Taxotere 61 DOXIL 61 Viread Emtriva 61 anthracycline chemotherapy 61 relapsed ALL 61 transarterial 61 desvenlafaxine succinate 61 undergone radical prostatectomy 61 transrectal ultrasound guided 61 nicardipine 61 null responder HCV 61 TORISEL 61 4mg/kg 61 lymphoma subtypes 61 partial remissions 61 hematologic parameters 61 Pegylated Liposomal Doxorubicin 61 Toxicities 61 randomized multicenter trial 61 external beam radiotherapy 61 allogeneic stem cell 61 hyperphenylalaninemia HPA due 61 Castration Resistant Prostate Cancer 61 Vascugel ® 61 Leucovorin 61 MCyR 61 hemodialysis patients 61 FDG uptake 61 antibody MAb 61 Heterozygous Familial Hypercholesterolemia 61 prednisone prednisolone plus 61 haematological 61 tapentadol ER 61 pyridostigmine 61 #mg dose [002] 61 flutamide 61 standard chemotherapy regimens 61 Retreatment 61 RAS mutations 61 LCP Tacro TM 61 evaluating Actimmune 61 retrospective cohort 61 beta 1a 61 candesartan cilexetil 61 q8h 61 Mitoxantrone 61 FVIIa 61 ErbB2 positive 61 nonmetastatic prostate cancer 61 plus prednisone 61 malignant cancerous 61 Randomized Evaluation 61 prucalopride 61 de novo kidney transplant 61 mcg albinterferon alfa 2b 61 Xeloda ® 61 non CF bronchiectasis 61 thoracoscopic lobectomy 61 Aflibercept 61 Patients Receiving 61 relapsed SCLC 61 advanced hepatocellular carcinoma 61 chlorambucil 61 radiolabeled TM# 61 platinum refractory 61 Febrile neutropenia 61 Campath alemtuzumab 61 taxane chemotherapy 61 doxorubicin docetaxel 61 FDG-PET/CT 61 KNS # 61 micafungin 61 Vidaza azacitidine 61 epithelial tumors 61 serum lipid levels 61 panitumumab Vectibix 61 AVODART 61 warfarin dosage 61 CTEPH 61 Metastatic Melanoma 61 infliximab monotherapy 61 hMG 61 GAMMAGARD 61 DAPT 61 pT2 61 cancer mCRC 61 Temodar ® 61 allogeneic hematopoietic stem cell 61 lymphoproliferative disorders 61 GRNVAC1 61 Hepatocellular Carcinoma HCC 61 Waldenstrom macroglobulinemia 61 Patients Treated With 61 telaprevir dosing 61 cytoreductive nephrectomy 61 corticosteroid dexamethasone 61 PROCHYMAL 61 MoxDuo TM IR 61 temozolomide Temodar 61 Subgroup analysis 61 IMiDs 61 lymphocyte counts 61 Neupogen ® 61 mitoxantrone 61 AGILECT ® 61 etoposide 61 Parathyroid Hormone 61 EGFR mutation positive 61 placebo dexamethasone 61 Azacitidine 61 B7 H3 61 ibandronate 61 abiraterone acetate 61 denileukin diftitox 61 PegIFN RBV 61 Epratuzumab 61 relapsed refractory multiple myeloma 61 Tipranavir 61 Angiotensin Converting Enzyme 61 aromatase inhibitor AI 61 acyclovir Lauriad R 61 unfractionated heparin UFH 61 oral Hycamtin 61 TroVax ® 61 IV NSCLC 61 histologic subtype 61 Cloretazine ® 61 renal artery stenting 61 pharmacodynamic parameters 61 idraparinux 61 conventional DMARDs 61 ORAL HYCAMTIN 61 tamoxifen Nolvadex ® 61 carboplatin paclitaxel 61 Estrogen Receptor 61 Hypotension 61 underwent liver transplantation 61 Kaplan Meier analysis 61 BEACOPP 61 SNT MC# 61 Tasigna prolongs 61 hepatic encephalopathy HE 61 Breast conserving 61 postmenopausal osteoporotic women 61 lymphoid malignancies 61 oral ridaforolimus 61 Lenalidomide 61 nadroparin 61 Myelodysplastic Syndrome 61 maximally tolerated dose 61 alefacept 61 pamidronate 61 de novo AML 61 piperacillin tazobactam 61 ovarian carcinoma 61 refractory myeloma 61 Tumors shrank 61 Neulasta ® 61 oral FTY# 61 interleukin IL -# 61 Allogeneic 61 irinotecan chemotherapy 61 BENICAR 61 MYDICAR 61 Proellex TM 61 Interferon beta 1a 61 morphometric vertebral fractures 61 diagnosed multiple myeloma 61 neratinib 61 Thalomid ® 61 plus DOXIL 61 IRX 2 61 Myocardial Perfusion Imaging 61 histone deacetylase HDAC inhibitor 61 renal biopsy 61 IMPACT DCM 61 lymphocytosis 61 CIN2 + 61 taxotere 61 SUVmax 61 5-fluorouracil/leucovorin 61 gadobutrol 61 temozolomide TMZ 61 MYLOTARG 61 malignant ascites 61 androgen deprivation 61 NAVISTAR R 61 EndoTAG TM -1 61 Triapine 61 pegylated IFN 61 pegfilgrastim 61 dose Iluvien 61 Adjunctive 61 colorectal cancer liver metastases 61 tenofovir emtricitabine 61 huN# DM1 61 HER2 positive cancers 61 patients undergoing CABG 61 Myocet 61 mitomycin 61 Cloretazine 61 HuMax EGFr 61 Evoltra ® 61 microtubule inhibitor 61 gastric carcinoma 61 FOLPI 61 pulmonary exacerbations 61 resectable pancreatic cancer 61 measurable tumor regressions 61 conditional logistic regression 61 cranial irradiation 61 IgM isotype 61 FDG PET scans 61 5 fluorouracil leucovorin 61 BRAF V#E mutation 61 mCi kg 61 chemotherapy docetaxel 61 pertuzumab 61 subcutaneous immunoglobulin 61 PROMACTA 61 Randomized Phase II 61 myeloablative 61 Phe restricted diet 61 FXIII 61 oxycodone CR 61 heFH 61 antiretroviral naive 61 metastatic gastric 61 AVONEX ® 61 targeted radiotherapeutic 61 pCR 61 Betaferon R 61 Cardiopulmonary bypass 61 irbesartan 61 vidofludimus 61 Chronic Myelogenous Leukemia CML 61 interstitial brachytherapy 61 APTIVUS ritonavir 61 receiving VICTRELIS 61 epithelial ovarian cancer 61 intact parathyroid hormone 61 Peg IFN 61 G#DT 61 Unresectable 61 preintervention 61 pegylated alpha interferon 61 ductal cancer 61 Panzem R NCD 61 paclitaxel chemotherapy 60 APPRAISE 60 nilotinib Tasigna 60 iPTH 60 stage IIIb 60 stage IIIA 60 antiarrhythmic drug 60 stable angina 60 assessing T DM1 60 serum phosphate 60 thrombocytopenic patients 60 budesonide MMX Phase III 60 postintervention 60 ICSI cycles 60 maximally tolerated lipid lowering 60 clodronate 60 mg Proellex 60 metastatic HER2 positive 60 nucleotide analog 60 inhaled iloprost 60 erythropoietic 60 unstable angina pectoris 60 Copegus ribavirin 60 inhaled treprostinil 60 Refractory Hodgkin Lymphoma 60 cutaneous squamous cell carcinoma 60 HDL Selective Delipidation 60 trastuzumab Herceptin 60 Relapsed Refractory 60 ICD therapy 60 including eniluracil ADH 60 tipranavir 60 pemetrexed Alimta 60 dirucotide MBP# 60 radiographic outcomes 60 proton MR spectroscopy 60 epirubicin cisplatin 60 HDR brachytherapy 60 deferoxamine 60 HBeAg + 60 intravenous diuretics 60 BARACLUDE ® 60 QTc prolongation 60 Chronic HCV 60 Advanced Melanoma 60 rFVIIa 60 anthracycline containing 60 antiandrogens 60 TAXOTERE ® 60 oncologic outcomes 60 Phase #b/#a clinical 60 Traficet EN 60 anastrazole 60 cisplatin chemotherapy 60 Epoetin alfa 60 T2DM 60 Acute Coronary Syndromes ACS 60 Nebulized 60 metastatic malignant melanoma 60 Cimzia ® certolizumab pegol 60 tanespimycin 60 serum urate 60 Zevalin consolidation 60 HCV SPRINT 60 chronic myeloid 60 myelofibrosis polycythemia vera 60 MDS AML 60 pulmonary artery banding 60 atorvastatin #mg 60 metastatic pancreatic 60 surgically resectable 60 percutaneous vertebroplasty 60 H. pylori eradication 60 doublet chemotherapy 60 relapsed CLL 60 bortezomib Velcade 60 neutropaenia 60 primary hypercholesterolemia 60 GnRH agonists 60 previously untreated follicular 60 prostate cancer PCa 60 multivariable Cox 60 leukemia CLL 60 IBS C 60 ACAPODENE TM 60 pegylated liposomal doxorubicin PLD 60 acute mania 60 stage IIIB IV 60 ELACYT 60 bleomycin 60 unresectable stage 60 Solazed 60 EGFR HER2 60 IV Busulfex 60 tumor biopsies 60 SCIg 60 Acute Ischemic Stroke 60 lomitapide 60 TAXOTERE R 60 dose cytarabine 60 ® lenalidomide 60 intravesical infusion therapy 60 efavirenz EFV 60 mg administered orally 60 paclitaxel Taxol 60 antithrombotic therapy 60 histologically proven 60 ß blockers 60 farletuzumab 60 genotype 1a 60 Pegasys plus Copegus 60 Granulocyte Colony Stimulating Factor 60 RhuDex TM 60 prospective observational cohort 60 Mg Uk 60 antiangiogenic agents 60 RE LY 60 Stage IIIb 60 ximelagatran 60 Sipuleucel T 60 Perforomist Inhalation Solution 60 aromatase inhibitors AIs 60 Belldegrun 60 subcutaneous PRO 60 hip resurfacing arthroplasty 60 ACTOS ® 60 kidney urologic 60 cervical carcinoma 60 SNT-MC#/idebenone 60 AMEVIVE 60 statin monotherapy 60 non splenectomized 60 Erlotinib 60 Elotuzumab 60 Genz # 60 cilostazol 60 HBeAg negative 60 commercialize deforolimus 60 Ranibizumab 60 Cytoxan 60 Hydroxyurea 60 atypical hyperplasia 60 follicular NHL 60 Gemzar ® 60 CR# vcMMAE 60 sustained virological response 60 palifermin 60 olmesartan 60 PROCRIT R 60 MYDICAR ® 60 neurocognitive function 60 bolus dose 60 severe neutropenia 60 tumors GIST 60 Alocrest 60 Diabetic Foot Ulcer 60 Roche Herceptin 60 radical retropubic prostatectomy 60 ductal breast cancer 60 plus prednisone prednisolone 60 EBRT 60 IFN α 60 surgical debulking 60 gemcitabine Gemzar 60 ALA PDT 60 Fludara ® 60 Solid Tumours 60 recombinant FSH 60 mCRC patients 60 Intervention Effectiveness 60 PD LID 60 bacterial prostatitis 60 viral kinetics 60 romiplostim 60 bladder carcinoma 60 sustained virologic response 60 Elitek 60 basiliximab 60 Philadelphia Chromosome Positive 60 Allovectin 7 ® 60 neutrophil counts 60 alemtuzumab Campath 60 euthymic patients 60 REVIVE Diabetes 60 demonstrated clinically meaningful 60 tumor regressions 60 nab paclitaxel 60 GISTs 60 HCV RESPOND 2 60 LNG IUS 60 Xanafide 60 ductal adenocarcinoma 60 ritonavir boosted lopinavir 60 advanced HER2 positive 60 oblimersen 60 mRCC 60 Daclizumab 60 octreotide 60 baminercept 60 depsipeptide 60 hypomethylating agents 60 Medullary thyroid cancer 60 ROCKET AF 60 metastatic hormone refractory 60 sarcomatoid 60 Fludara 60 vitamin B# folic acid 60 #mg/m# [002] 60 vinca alkaloid 60 oral diclofenac 60 radiochemotherapy 60 aplastic anemia AA 60 lenalidomide Revlimid 60 mixed hyperlipidemia 60 3D conformal radiation 60 relapsed Acute Myeloid 60 recombinant PSMA vaccine 60 HBeAg positive patients 60 VADT 60 fosamprenavir 60 thorough QT 60 TMP SMX 60 MIRAPEX ER 60 intradermal injection 60 pegylated interferon alfa 2b 60 mammographic density